The latest reference price list of romilastin in 2025

Romiplostim is a recombinant human thrombopoietin receptor agonist, mainly used to treat chronic immune thrombocytopenic purpura (ITP) and other diseases. With the official launch of this drug in China and its successful inclusion in the national medical insurance directory, patient accessibility has been significantly improved. Especially after medical insurance coverage, drug costs have dropped significantly, reducing the financial burden of long-term treatment for patients.

As of2025, there are two main versions of romiplostim in the domestic market: imported drugs and domestic drugs, and there are certain differences in prices. The imported version mainly comes from international pharmaceutical companies such as Amgen, and the price of one specification is about more than 2,000 yuan. The domestic version has gradually become available on the market. Supported by medical insurance policies, its price is more affordable, about more than a thousand yuan. Domestic drugs strictly follow national drug regulatory standards in terms of quality control, providing patients with more choices.

It is worth noting that although romiplostim has been included in the medical insurance catalog, the actual reimbursement ratio will be affected by regional medical insurance policies, hospital levels and the patient's specific condition. Some areas implement strict approval procedures for medical insurance drugs, and patients need to be evaluated and registered by a doctor before use. Therefore, it is recommended to consult the local hospital pharmacy or medical insurance department in detail before use to confirm the specific cost proportion and process.

Overall,2025The price structure of romiplostim will be more reasonable, especially with the support of medical insurance policies, patient availability has been greatly improved. Whether it is imported drugs or domestic drugs, they can meet the treatment needs of patients with different economic conditions. For patients with chronic ITP who have relied on platelet-raising therapy for a long time, this is undoubtedly a positive change that will help improve the continuity and effectiveness of disease management.

Reference: https://en.wikipedia.org/wiki/Romiplostim